Global Prevalence of ATTR-CM in Participants With HFpEF

Inclusion Criteria:

1. Medical history of heart failure (HF) with:

2. At least 1 episode with clinical evidence of HF (without hospitalization) bysigns or symptoms of volume overload or elevated intracardiac pressures thatrequired/requires treatment with a diuretic for improvement; OR

3. 1 prior hospitalization for HF.

4. Left ventricular ejection fraction (LVEF) >40%.

5. End-diastolic interventricular septal wall thickness (IVST) ≥12 mm.

6. Willing and able to undergo scintigraphy.

Exclusion Criteria:

1. Diagnosis of heart failure with reduced ejection fraction (HFrEF) (EF ≤40%).

2. Prior clinical history of myocardial infarction, CABG or multi-vessel obstructivecoronary disease (>50% stenosis of ≥2 epicardial coronary arteries).

3. Presence or history of any severe valvular heart disease (obstructive orregurgitant).

4. A confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiacsarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversiblecauses, hypertrophic obstructive cardiomyopathy with known genetic etiology, orknown pericardial constriction.

5. Any type of diagnosed amyloidosis (eg, amyloid A amyloidosis, primary [light chain]amyloidosis) or prior diagnosis of ATTR-CM.